NEW YORK – UK-based proteomics start-up Kinomica aims to use mass spectrometry-based phosphoproteomics to inform drug development and patient treatment with a focus on oncology.
The company, which was spun out of Queen Mary University of London's Barts Cancer Institute, is currently focused on developing a test for identifying acute myeloid leukemia patients likely to respond to the drug midostaurin.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
